The Chinese tumor registration data released by the National Cancer Center in 2016 shows that the incidence of multiple myeloma in my country is about ten 1 in 10,000, ranking second in hematological malignancies, with a high incidence age of 40-70 years old. With the aging of the population and the improvement of the level of diagnosis, the incidence of multiple myeloma in my country is increasing year by year, and it is showing a younger trend.
Multiple myeloma is a clonal plasma cell malignancy with high cytogenetic heterogeneity. There is still no cure. Multiple myeloma often presents with bone damage, anemia, hypercalcemia, kidney damage, etc. Most patients face the dilemma of recurrence, short survival and limited treatment options.
Since myeloma treatment drugs entered China in 2005, with the unremitting efforts of clinicians, scientific research experts and innovative pharmaceutical companies, new drugs have been continuously developed and applied, and new joint diagnosis and treatment models have been continuously Emerging, bringing hope to patients for treatment. With the successful development of targeted, immune and other therapeutic drugs and the clinical application of new technologies such as autologous hematopoietic stem cell transplantation, the treatment level of multiple myeloma has been significantly improved. However, relapsed/refractory multiple myeloma is still a clinical problem. insurmountable problem. At the same time, how to help patients deepen their understanding of myeloma, avoid detours in the treatment process, and achieve standardized self-management is a common challenge faced by doctors and patients.
Every March “International Myeloma Care Month”, a series of disease popularization activities are carried out in various online formats such as live lectures, patient stories, cartoon pictures and texts. The authoritative experts in the field popularize the knowledge of myeloma diagnosis, treatment and nursing, further enhance the public’s attention to myeloma, establish the basic understanding of patients and their families on the standardized diagnosis and treatment methods of myeloma, and enhance the social care for the myeloma patient group.
In order to popularize the knowledge of myeloma diagnosis and treatment, help patients face the tumor correctly, improve treatment confidence, and strengthen the cognition and management level of patients and their families on myeloma, “Multiple The Myeloma Patient Handbook and Diffuse Large B-Cell Lymphoma Patient Handbook were released in December last year. The handbooks present scientific disease treatment and nursing knowledge to patients in a vivid form. With the theme of “New Hope Cancer Disease Popularization and Patient Care”, 150 patient education activities are planned to be held nationwide within a year, covering 100 experts, benefiting more than 20,000 patients and their families, and answering questions for the majority of patients . Myeloma science covers topics such as “the concept of front-line therapy and nuclear export protein inhibitors”, “the introduction and treatment of myeloma and rational drug use”, “disease follow-up and precautions in daily life”.
（Pan Jiayi）